April 12, 2021
FDA: Class I recall of Medtronic’s Valiant Navion Thoracic Stent Graft System
Editor's Note
The Food & Drug Administration (FDA), on April 9, identified the recall of Medtronic’s Valiant Navion Thoracic Stent Graft System as Class I, the most serious.
The recall was initiated because of the risk of stent fractures and endoleak concerns. The system is used to repair lesions of the descending thoracic aorta.
There have been 11 reported issues, including two injuries and one death. Distribution dates were November 12, 2018 to February 10, 2021.
Read More >>
Free Daily News
- Quality Improvement: Reduce Specimen Labeling Errors
- Staffing Strategy: Grow Your Middle Management
- Olympus issues voluntary labeling update for bronchoscopes used with laser therapy equipment
- NorthStar Anesthesia scales ASC partnerships in Georgia with transparent, clinician-driven model
- Targeted intraoperative radiation slashes pancreatic cancer recurrence to 5%
- Ambient AI reshapes nursing workflows and boosts patient interaction
- Session: Developing a complex spine and total joint service line program in the ASC
- Session: The importance of having a comprehensive plan to prevent workplace violence in ASCs
- Session: Automate to elevate—Streamlining pre-, postoperative processes for better outcomes in ASCs
- Transparent oversight is key to safe surgical innovation
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement